With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...

The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

近两年随着数据中心快速发展推动电力需求飙升，全球电力变压器市场供应紧张的问题日益突出，供货周期延长至3到4年。变压器对于改变电压至关重要，可使电力高效地从发电厂流向最终用户。挪威咨询机构睿咨得能源预测，到2030年，全球变压器市场规模有望从目前的480亿美元大幅提升至670亿美元。该机构分析师直言，电力变压器是目前供应不足问题最突出的关键电网设备，由于增产困难，该产业正面临前所未有的压力，预计变压 ...

【环球时报综合报道】减肥药市场竞争近日不断升温。据路透社4日报道，维京治疗周一公布了其试验性药物VK2735的一期数据，显示其在较高剂量下相比早期配方能更有效地减轻患者体重。而阿斯利康周一发布的口服药片AZD5004也呈现出不错的数据。这提升了这两家 ...

The Company is also evaluating an oral tablet formulation of VK2735 (ClinicalTrials.gov Identifier: NCT05203237). Phase 1 trial results demonstrated up to a 3.3% placebo-adjusted mean weight reduction ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

很明显减肥药物淘金热只会愈演愈烈。对减肥药物的极高需求提供了相当大的机会。投资者对Viking打入减肥药市场的潜力表示看好，今年该公司股价已上涨三倍。据预测，到2030年，减肥药市场规模将达到1300亿美元。投资者不应该对Viking所面临的日益激烈的竞争感到气馁，这家生物技术公司显然拥有一种有效的药物，并且在开发以及商业化药物方面进展顺利。

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...